-+ 0.00%
-+ 0.00%
-+ 0.00%

Novartis announced today that the European Medicines Agency's Human Medicines Committee has adopted a positive opinion recommending approval of Kesanting® for the treatment of polymyalgia rheumatica.

智通財經·09/18/2026 15:09:04
語音播報
Novartis announced today that the European Medicines Agency's Human Medicines Committee has adopted a positive opinion recommending approval of Kesanting® for the treatment of polymyalgia rheumatica.